Zelboraf 240mg (Vemurafenib Tablet) 240mg

Zelboraf 240mg tablets contain vemurafenib, a targeted therapy for certain types of cancer. This oral medication is prescribed to slow disease progression in specific melanoma cases. Suitable for ambient storage, it offers a 56-tablet pack size for prescribed treatment courses.

Strength

240mg

Pack Size

56s

Storage

Ambient

Manufacturer / TM Owner

Roche Pharma

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Vemurafenib is used to treat melanoma, a type of skin cancer, when the cancer has spread or cannot be removed by surgery. It targets cancer cells with a specific genetic mutation. This medication may also be used in other cancer types as determined by a healthcare provider. Patients often ask, what is vemurafenib used for, and it is primarily indicated for advanced melanoma treatment.

Side Effects

Vemurafenib works by blocking signals in cancer cells that promote growth. Many patients experience changes in skin condition, such as rash or sensitivity, during treatment. Some may notice fatigue or joint discomfort as common effects. These responses vary by individual and should be monitored by a healthcare professional.

Precautions & Warnings

Store vemurafenib tablets at room temperature away from moisture and heat. Keep the medication in its original packaging until ready to use. Avoid crushing or splitting tablets unless instructed by a doctor. Always handle with clean hands and follow local disposal guidelines for unused medication.

Avoid Interactions

Vemurafenib may interact with other medications, including certain antidepressants and antibiotics. Grapefruit and grapefruit juice can affect how vemurafenib works. Strong CYP3A4 inhibitors or inducers may alter vemurafenib levels in the body. Discuss all current medications with a healthcare provider before starting treatment.

Frequently Asked Questions

Vemurafenib is primarily used to treat advanced melanoma with a specific genetic mutation.

Store at room temperature in the original packaging, away from moisture and heat.

Do not crush or split tablets unless specifically instructed by a healthcare provider.

Common effects may include skin rash, fatigue, or joint discomfort during treatment.

Yes, it may interact with CYP3A4 inhibitors, inducers, and certain other medications.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.